The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer.
Alice Dewdney
Disclosure not yet available
David Cunningham
Disclosure not yet available
Josep Tabernero
Disclosure not yet available
Bengt Glimelius
Disclosure not yet available
Andres Cervantes
Disclosure not yet available
Diana M. Tait
Disclosure not yet available
Gina Brown
Disclosure not yet available
Andrew Wotherspoon
Disclosure not yet available
David Gonzalez de Castro
Disclosure not yet available
Ian Chau
Disclosure not yet available